摘要
目的:探讨FOLFIRINOX方案治疗Ⅳ期胰腺癌与吉西他滨联合卡培他滨方案的效果差异。方法:选取本院病理学确诊的Ⅳ期胰腺癌患者68例,收集时间2016年5月-2018年5月,其中34例患者接受FOLFIRINOX方案治疗(A组)、34例患者接受吉西他滨联合卡培他滨方案治疗(B组),对比两组患者的临床疗效、预后及毒副反应。结果:A组患者PR 68.75%、SD 25.00%、PD 6.25%,B组患者PR 41.18%、SD 44.12%、PD 14.71%,两组比较差有统计学意义(P<0.05);A组患者白细胞减少、恶心呕吐发生程度显著高于B组患者,两组比较差异均有统计学意义(P<0.05);A组患者6、12个月生存率与B组比较差异均无统计学意义(P>0.05);A组患者的PFS时间9.0个月长于B组患者的7.0个月(P<0.05),A组患者的OS时间10.0个月长于B组患者的8.0个月(P<0.05)。结论:FOLFIRINOX方案治疗Ⅳ期胰腺癌的效果优于吉西他滨联合卡培他滨方案,但是毒副反应发生率相对较高,为一般状况良好Ⅳ期胰腺癌患者的较好选择。
Objective:To investigate the difference of efficacy between Gemcitabine and Capecitabine in stageⅣpancreatic cancer treated with FOLFIRINOX regimen.Method:68 pancreatic cancer patients with stageⅣwere confirmed in our hospital pathological cases,the collection time from May 2016 to May 2018,34 patients were treated with FOLFIRINOX regimen(group A),34 patients were treated with gemcitabine combined with Capecitabine therapy(group B),the clinical curative effect,prognosis and adverse reaction of two groups were compared.Result:Patients in group A of PR 68.75%,SD 25.00%,PD 6.25%,group B of PR 41.18%,SD 44.12%,PD 14.71%,the differences were statistically significant(P<0.05);the leukopenia,nausea and vomiting in group A were significantly higher than those in group B,the differences were statistically significant(P<0.05);the survival rate of 6 and 12 months of two groups had no significant difference(P>0.05);the PFS time of group A was 9 months longer than 7 months of group B(P<0.05),the OS time of group A was 10 months longer than 8 months of group B(P<0.05).Conclusion:The FOLFIRINOX regimen is superior to the Gemcitabine and Capecitabine regimen in the treatment of stageⅣpancreatic cancer,but the incidence of toxic side effects is relatively high,it is a better choice for general good condition patients with stageⅣpancreatic cancer.
作者
陈泽勉
苏国钿
赵楚英
CHEN Zemian;SU Guodian;ZHAO Chuying(Chaozhou Central Hospital,Chaozhou 521000,China)
出处
《中国医学创新》
CAS
2018年第30期37-41,共5页
Medical Innovation of China
作者简介
通信作者:陈泽勉。
